Roberge D, Muanza T, Blake G, Shustik C, Vuong T, Freeman C R
Department of Radiation Oncology and Division of Hematology, Department of Medicine, McGill University Health Centre, Montreal, Quebec H3G 1A4, Canada.
Br J Dermatol. 2007 Jan;156(1):57-61. doi: 10.1111/j.1365-2133.2006.07559.x.
Patients with mycosis fungoides (MF) experience frequent disease recurrences following total skin electron irradiation (TSEI) and may benefit from adjuvant therapy.
To review the McGill experience with adjuvant alpha-interferon (IFN) in the treatment of MF.
From 1990 to 2000, 50 patients with MF were treated with TSEI: 31 with TSEI alone and 19 with TSEI + IFN. Median TSEI dose was 35 Gy. In the TSEI + IFN group, IFN was given subcutaneously at 3 x 10(6) units three times per week starting 2 weeks prior to start of TSEI, continued concurrently with the radiation and for an additional 12 months following TSEI. The TSEI alone group included 16 men and 15 women with a median age of 61 years (range 31-84). The TSEI + IFN group included 14 men and five women with a median age of 51 years (range 24-83). Clinical stage was IA, IB, IIA, IIB, III and IVA in 2, 9, 4, 8, 1 and 7 patients of the TSEI group and 0, 3, 3, 7, 4 and 2 patients of the TSEI + IFN group.
Median follow up for living patients was 70 months. All patients responded to treatment. Complete response (CR) rate was 65% following TSEI and 58% following TSEI + IFN (P = 0.6). Median overall survival (OS) was 61 months following TSEI and 38 months following TSEI + IFN (P = 0.4). Acute grade II-III dermatitis was seen in all patients. Fever, chills or myalgia were seen in 32% of patients treated with TSEI + IFN.
Concurrent IFN and TSEI is feasible, with acceptable toxicity. Even when controlling for disease stage, the addition of IFN did not appear to increase CR rate, disease-free survival or OS.
蕈样肉芽肿(MF)患者在接受全身皮肤电子束照射(TSEI)后疾病频繁复发,辅助治疗可能有益。
回顾麦吉尔大学使用辅助性α-干扰素(IFN)治疗MF的经验。
1990年至2000年,50例MF患者接受了TSEI治疗:31例仅接受TSEI治疗,19例接受TSEI + IFN治疗。TSEI的中位剂量为35 Gy。在TSEI + IFN组中,IFN在TSEI开始前2周开始皮下注射,剂量为3×10⁶单位,每周3次,在放疗期间持续使用,并在TSEI后再持续12个月。仅接受TSEI治疗的组包括16名男性和15名女性,中位年龄为61岁(范围31 - 84岁)。TSEI + IFN组包括14名男性和5名女性,中位年龄为51岁(范围24 - 83岁)。TSEI组的2、9、4、8、1和7例患者以及TSEI + IFN组的0、3、3、7、4和2例患者的临床分期分别为IA、IB、IIA、IIB、III和IVA期。
存活患者的中位随访时间为70个月。所有患者对治疗均有反应。TSEI后完全缓解(CR)率为65%,TSEI + IFN后为58%(P = 0.6)。TSEI后的中位总生存期(OS)为61个月,TSEI + IFN后为38个月(P = 0.4)。所有患者均出现急性II - III级皮炎。32%接受TSEI + IFN治疗的患者出现发热、寒战或肌痛。
IFN与TSEI联合使用是可行的,毒性可接受。即使在控制疾病分期的情况下,添加IFN似乎也未提高CR率、无病生存期或OS。